Creative Medical Technology Holdings, Inc. (CELZ) is an innovative biotech company that is making a significant impact in the field of regenerative medicine. The company, whose shares trade under the stock symbol CELZ, operates in the biotechnology sector and develops novel stem cell therapies for a variety of medical conditions.
The vision of CELZ is to revolutionize the treatment of debilitating and often life-threatening conditions that demand innovative solutions. It aims to surpass the limitations of traditional treatments using the transformative potential of the human body's ability to regenerate. Utilizing the intrinsic restorative capacity of stem cells, the company is at the forefront of creating breakthrough treatments for a range of conditions, such as erectile dysfunction, kidney failure, heart disease, and a variety of degenerative neurological conditions.
The company's approach to leadership is also noteworthy. Creative Medical Technology Holdings, Inc. boasts an experienced and dynamic team of scientists, researchers and business professionals. This stellar team is driven by a shared dedication to rigorous science, innovative thinking, and a commitment to bringing groundbreaking therapies from conception to reality.
Although they are a relatively young company, having been incorporated in Nevada in 1998 and commenced operations in 2002, they have rapidly emerged as major players in the regenerative medicine space. The company has a robust portfolio of ongoing projects, ranging from early-stage research and development to clinical trials. Leveraging extensive in-house capabilities and strategic partnerships, the company aims to expedite the translational process from lab to patient, while maintaining a strict adherence to safety and regulatory guidelines.
Key to the success of Creative Medical Technology Holdings, Inc. has been its focus on the development of innovative, stem cell-based technologies. This includes patented technologies such as ImmCelz®, a proprietary immunotherapy which uses the patient's own cells to address a variety of medical indications. Additionally, the company recently received FDA clearance for CaverStem®, a stem cell procedure for treating erectile dysfunction in men.
CELZ is listed on the OTC Market, and is focused not only on improving patients' lives, but also on delivering value to their investors. Despite the inherent risks in biotechnology investment, the promising nature of their technological platforms, combined with their steadfast focus on advancing regenerative medicine, makes Creative Medical Technology Holdings, Inc. a company to watch.
In conclusion, Creative Medical Technology Holdings, Inc. embodies the exciting, transformative potentials of the burgeoning field of regenerative medicine. With their commitment to employing stem cell technology to address unmet medical needs, the company offers new hope for individuals with debilitating illnesses and conditions, thus truly living up to their name – Creative.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Creative Medical Technology Holdings has completed enrollment and treatment for its FDA-cleared ADAPT trial, including the opioid cohort, for CELZ-201 / Olastrocel, a regenerative cell therapy for chronic lower back pain. This milestone allows the company to transition to data maturation and regulatory planning, aiming for RMAT evaluation and Phase 3 discussions with the FDA. The completion also reduces active trial expenses, extending the company's operating runway without immediate further fundraising.
Creative Medical Technology Holdings Inc (CELZ) is considered 171.4% overvalued according to its GF Value™, despite a Roth Capital analyst reaffirming a Buy rating with a $20 price target due to promising ADAPT trial results. The company exhibits an extremely high Price-to-Sales ratio of 1330x, signaling high investor expectations for future revenue growth, although it currently reports zero revenue and is unprofitable. CELZ's GF Score™ is 28/100, reflecting significant weaknesses in profitability and growth, alongside strong financial health with no debt.
Creative Medical Technology Holdings Inc (CELZ) is considered 142.9% overvalued based on GuruFocus' GF Value™ metric, trading at $1.19 per share against an estimated fair value of $0.49. Despite the recent completion of its ADAPT clinical trial for CELZ-201, the company exhibits an extremely high Price-to-Sales ratio of 1190.1x and a low GF Score™ of 28/100, reflecting significant challenges in profitability and growth. While CELZ boasts strong financial strength with no debt, investors are cautioned about its early-stage, high-risk nature and the reliance on future growth expectations that are not yet reflected in revenues or earnings.
Avalon Holdings Corporation (AWX) shares surged over 10% in pre-market trading after reporting strong second-quarter financial results, with earnings up to 23 cents per share and sales increasing to $20.898 million. The article also lists other stocks experiencing significant pre-market movements, including both gainers and losers, along with reasons for their volatility such as company announcements or recent trading performance.